Loading...

CCCC C4 THERAPEUTICS INC Investments/Divestments 8-K Filing

C4 T

CCCC

C4 THERAPEUTICS INC

(CCCC)

2023 8-K

Management Change

Financial Update

Research Partnership

Financial Results

Future Milestones

Financial Results Report

Stock Offering Announcement

Presentation Update

Clinical Trial Agreement

Clinical Trial Update

Phase 1 Trial Progress

Increase in authorized shares

Clinical Trials

Director Retirement

Financial Results

Financial Update

Clinical Update

Director Appointment

Financial Results

Management Changes

Management Changes

Stock Option Amendment

Director Changes

Earnings Report

Annual Meeting Results

Resignation and Appointment...

Earnings Report

Option Repricing

Research Collaboration and ...

Financial Results Announcement

Investor Presentation

Restructuring Plan

Clinical Trial Update

License Agreement with Merc...

Appointment of Director

Earnings Reports

Earnings Report

Appointment of Chief Medica...

License Agreement and Stock...

Earnings Report

Earnings Reports

Resignation of Chief Medica...

Press Release and Investor ...

External Links:

C4 Therapeutics, Inc. entered into a License and Collaboration Agreement with Merck to develop and commercialize degrader-antibody conjugates (DACs) for cancer treatment, with potential payments of up to $2.5 billion.

AI Assistant

C4 THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.